CSL Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
companies in this sector in the United States:
Eisai Company Limited
sales of $5.79 billion
of which 88%
was Pharmaceutical Business),
Daiichi Sankyo Company Limited
of which 93%
was Prescription drugs), and
of which 35%
was Softgel Technologies).
CSL Limited reported sales of $8.54 billion
June of 2019.
increase of 7.9%
versus 2018, when the company's sales were $7.92 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2014, sales have increased a total of 55%).
Sales of Seqirus saw an increase
11.8% in 2019, from
$910.40 million to $1.02 billion.